BIOCAUSE HEILEN PHARMA released its half-year performance, with a net profit attributable to the parent company of 18.5471 million yuan, a decrease of 72.92%
BIOCAUSE HEILEN PHARMA released its semi-annual report for 2025, with operating revenue of 235 million yuan, a year-on-year decrease of 2.93%; net profit attributable to the parent company was 18.5471 million yuan, a year-on-year decline of 72.92%. After deducting non-recurring gains and losses, the net profit was 4.4162 million yuan, a year-on-year decrease of 93.21%. The basic earnings per share were 0.06 yuan. The company plans to distribute 4.5 additional shares for every 10 shares to all shareholders and actively promote the implementation of fundraising investment projects, including the safety and environmental upgrade technical reform project for the hydrolysis and acidification position of ibuprofen raw materials and the construction of high-end pharmaceutical formulation internationalization projects
According to the Zhitong Finance APP, BIOCAUSE HEILEN PHARMA (301211.SZ) released its semi-annual report for 2025, showing an operating income of 235 million yuan, a year-on-year decrease of 2.93%. The net profit attributable to shareholders of the listed company was 18.5471 million yuan, a year-on-year decrease of 72.92%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 4.4162 million yuan, a year-on-year decrease of 93.21%. The basic earnings per share were 0.06 yuan. In addition, it is proposed to distribute 4.5 additional shares for every 10 shares to all shareholders.
During the reporting period, the company actively promoted the implementation of fundraising investment projects. The safety and environmental upgrade technical reform project for the hydrolysis and acidification position of ibuprofen raw materials has passed the on-site joint acceptance by the housing construction department and has begun trial production. The high-end pharmaceutical formulation internationalization project obtained the construction engineering construction permit on June 5, 2025, and is currently in the construction phase
